Short Term
Mean Reversion
Neutral
Trend
Neutral
Event
Neutral
Halo Model
MQV
Very Strong
GARP
Very Strong
MQV Small
Neutral
Momentum
Price
Very Weak
Earnings
Very Strong
Growth
Earnings
Very Strong
Dividends
Very Strong
Quality
Capital Efficiency
Very Strong
Balance Sheet
Very Strong
Website
N/ATelephone
N/A
Address
Description
Tissue Repair Ltd. is a clinical stage bio pharmaceutical company, which develops advanced wound healing products targeting applications in the chronic wound and aesthetic procedure aftercare markets, with the potential for further development of related technologies. The company has developed an ingredient that is designed for wound healing and the biologically active pharmaceutical ingredient behaves like a decoy cell that simulates a yeast infection, resulting in the stimulation of the body's own wound repair pathways. The company was founded by Tony Charara in 2012 and is headquartered in Sydney, Australia.
Market Cap
PE
EV/EBITDA
DIV Yield
Franking
Ex Dividend Date (est.)
52 weeks range
Low 0.19 - 0.5
Trade Value (12mth)
AU$7,871.00
1 week
6.17%
1 month
24.64%
YTD
95.45%
1 year
62.26%
All time high
0.83
EPS 3 yr Growth
209.50%
EBITDA Margin
%
Operating Cashflow
-$5m
Free Cash Flow Return
-24.80%
ROIC
-20.70%
Interest Coverage
N/A
Quick Ratio
14.30
Shares on Issue (Fully Dilluted)
60m
HALO Sector
Healthcare
Next Company Report Date
21-Aug-25
Ex Dividend Date (est.)
N/A
Next Dividend Pay Date (est.)
N/A
Reporting Currency
AUD
Short Sell (% of issue)
0.00
Date | Announcements |
---|---|
02 September 24 |
Re- Takeovers Panel - Media Release
×
Re- Takeovers Panel - Media Release |
30 August 24 |
2024 Annual General Meeting Date
×
2024 Annual General Meeting Date |
29 August 24 |
Panel Receives Application
×
Panel Receives Application |
22 August 24 |
Appendix 4E and Annual Report 30 June 2024
×
Appendix 4E and Annual Report 30 June 2024 |
22 August 24 |
Appendix 4G and Corporate Governance Statement
×
Appendix 4G and Corporate Governance Statement |
08 August 24 |
Tony Charara Co-founder appointed as CEO
×
Tony Charara Co-founder appointed as CEO |
31 July 24 |
Company Update - Presentation
×
Company Update - Presentation |
31 July 24 |
Quarterly Activities/Appendix 4C Cash Flow Report
×
Quarterly Activities/Appendix 4C Cash Flow Report |
25 July 24 |
TGA approval granted for Tissue Repair TR Pro
×
TGA approval granted for Tissue Repair TR Pro |
15 May 24 |
Application for quotation of securities - TRP
×
Application for quotation of securities - TRP |
09 May 24 |
Notice under ASX Listing Rule 3.10A
×
Notice under ASX Listing Rule 3.10A |
30 April 24 |
Quarterly Activities/Appendix 4C Cash Flow Report
×
Quarterly Activities/Appendix 4C Cash Flow Report |
04 April 24 |
Notification regarding unquoted securities - TRP
×
Notification regarding unquoted securities - TRP |
01 March 24 |
Change of Company Secretary
×
Change of Company Secretary |
29 February 24 |
Appendix 4D and Half Year Report to 31 December 2023
×
Appendix 4D and Half Year Report to 31 December 2023 |
30 January 24 |
Quarterly Activities/Appendix 4C Cash Flow Report
×
Quarterly Activities/Appendix 4C Cash Flow Report |
19 December 23 |
Third US Patent granted for Tissue Repair Glucoprime
×
Third US Patent granted for Tissue Repair Glucoprime |
20 November 23 |
Application for quotation of securities - TRP
×
Application for quotation of securities - TRP |
16 November 23 |
Change of Director's Interest Notice - Michael Silberberg
×
Change of Director's Interest Notice - Michael Silberberg |
15 November 23 |
Notification regarding unquoted securities - TRP
×
Notification regarding unquoted securities - TRP |
09 November 23 |
Notice under ASX Listing Rule 3.10A
×
Notice under ASX Listing Rule 3.10A |
30 October 23 |
Quarterly Activities/Appendix 4C Cash Flow Report
×
Quarterly Activities/Appendix 4C Cash Flow Report |
26 October 23 |
AGM Presentation
×
AGM Presentation |
26 October 23 |
Results of Meeting
×
Results of Meeting |
22 September 23 |
Notice of Annual General Meeting/Proxy Form
×
Notice of Annual General Meeting/Proxy Form |
Load More
Load Less
Historical data
Forecast data
Load More
Load Less
Historical data
Forecast data
Load More
Load Less
Historical data
Forecast data
Load More
Load Less
Percent of Issue
Value ($M)
Prior Change
7 Day Change
1 Month Change
3 Month Change
Access data on short interest, stock performance, and potential short-selling candidates across various markets to make informed decisions and optimize your trading strategies.
Unlock true investor intelligence
Research, trade and manage global markets from one place with HALO Global. It’s trading - the way you want it.
Get the latest insights and hot tips delivered right to your inbox
HALO Technologies Pty Ltd ABN 54 623 830 866 is a Corporate Authorised Representative No 1261916 of Macrovue Pty Ltd ABN 98 600 022 679 AFSL 484264. Macrovue Pty Ltd is a wholly owned subsidiary of HALO Technologies Pty Ltd.